Clinical Trial Update: Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide with nivolumab in relapsed or refractory multiple myeloma has been terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)
• nivolumab (nivolumab)

Snippet

Sponsor: Yvonne Efebera | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-30